306 related articles for article (PubMed ID: 17878479)
1. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer.
Heymach JV; Johnson BE; Prager D; Csada E; Roubec J; Pesek M; Spásová I; Belani CP; Bodrogi I; Gadgeel S; Kennedy SJ; Hou J; Herbst RS
J Clin Oncol; 2007 Sep; 25(27):4270-7. PubMed ID: 17878479
[TBL] [Abstract][Full Text] [Related]
2. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial.
Herbst RS; Sun Y; Eberhardt WE; Germonpré P; Saijo N; Zhou C; Wang J; Li L; Kabbinavar F; Ichinose Y; Qin S; Zhang L; Biesma B; Heymach JV; Langmuir P; Kennedy SJ; Tada H; Johnson BE
Lancet Oncol; 2010 Jul; 11(7):619-26. PubMed ID: 20570559
[TBL] [Abstract][Full Text] [Related]
3. Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer.
Choueiri TK; Ross RW; Jacobus S; Vaishampayan U; Yu EY; Quinn DI; Hahn NM; Hutson TE; Sonpavde G; Morrissey SC; Buckle GC; Kim WY; Petrylak DP; Ryan CW; Eisenberger MA; Mortazavi A; Bubley GJ; Taplin ME; Rosenberg JE; Kantoff PW
J Clin Oncol; 2012 Feb; 30(5):507-12. PubMed ID: 22184381
[TBL] [Abstract][Full Text] [Related]
4. Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial.
de Boer RH; Arrieta Ó; Yang CH; Gottfried M; Chan V; Raats J; de Marinis F; Abratt RP; Wolf J; Blackhall FH; Langmuir P; Milenkova T; Read J; Vansteenkiste JF
J Clin Oncol; 2011 Mar; 29(8):1067-74. PubMed ID: 21282537
[TBL] [Abstract][Full Text] [Related]
5. Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions.
Morabito A; Piccirillo MC; Falasconi F; De Feo G; Del Giudice A; Bryce J; Di Maio M; De Maio E; Normanno N; Perrone F
Oncologist; 2009 Apr; 14(4):378-90. PubMed ID: 19349511
[TBL] [Abstract][Full Text] [Related]
6. EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer.
Heymach JV; Lockwood SJ; Herbst RS; Johnson BE; Ryan AJ
Ann Oncol; 2014 Oct; 25(10):1941-1948. PubMed ID: 25057173
[TBL] [Abstract][Full Text] [Related]
7. Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study.
Natale RB; Bodkin D; Govindan R; Sleckman BG; Rizvi NA; Capó A; Germonpré P; Eberhardt WE; Stockman PK; Kennedy SJ; Ranson M
J Clin Oncol; 2009 May; 27(15):2523-9. PubMed ID: 19332730
[TBL] [Abstract][Full Text] [Related]
8. Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer.
Heymach JV; Paz-Ares L; De Braud F; Sebastian M; Stewart DJ; Eberhardt WE; Ranade AA; Cohen G; Trigo JM; Sandler AB; Bonomi PD; Herbst RS; Krebs AD; Vasselli J; Johnson BE
J Clin Oncol; 2008 Nov; 26(33):5407-15. PubMed ID: 18936474
[TBL] [Abstract][Full Text] [Related]
9. Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized Phase II study.
Boér K; Láng I; Llombart-Cussac A; Andreasson I; Vivanco GL; Sanders N; Pover GM; Murray E
Invest New Drugs; 2012 Apr; 30(2):681-7. PubMed ID: 20830502
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, placebo-controlled phase II study of vandetanib plus docetaxel/prednisolone in patients with hormone-refractory prostate cancer.
Horti J; Widmark A; Stenzl A; Federico MH; Abratt RP; Sanders N; Pover GM; Bodrogi I
Cancer Biother Radiopharm; 2009 Apr; 24(2):175-80. PubMed ID: 19409038
[TBL] [Abstract][Full Text] [Related]
11. A randomized, phase II study of vandetanib maintenance for advanced or metastatic non-small-cell lung cancer following first-line platinum-doublet chemotherapy.
Ahn JS; Lee KH; Sun JM; Park K; Kang ES; Cho EK; Lee DH; Kim SW; Lee GW; Kang JH; Lee JS; Lee JW; Ahn MJ
Lung Cancer; 2013 Dec; 82(3):455-60. PubMed ID: 24075125
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20.
Arnold AM; Seymour L; Smylie M; Ding K; Ung Y; Findlay B; Lee CW; Djurfeldt M; Whitehead M; Ellis P; Goss G; Chan A; Meharchand J; Alam Y; Gregg R; Butts C; Langmuir P; Shepherd F;
J Clin Oncol; 2007 Sep; 25(27):4278-84. PubMed ID: 17878480
[TBL] [Abstract][Full Text] [Related]
13. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.
Reck M; Kaiser R; Mellemgaard A; Douillard JY; Orlov S; Krzakowski M; von Pawel J; Gottfried M; Bondarenko I; Liao M; Gann CN; Barrueco J; Gaschler-Markefski B; Novello S;
Lancet Oncol; 2014 Feb; 15(2):143-55. PubMed ID: 24411639
[TBL] [Abstract][Full Text] [Related]
14. Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904.
Coleman RL; Moon J; Sood AK; Hu W; Delmore JE; Bonebrake AJ; Anderson GL; Chambers SK; Markman M
Eur J Cancer; 2014 Jun; 50(9):1638-48. PubMed ID: 24709487
[TBL] [Abstract][Full Text] [Related]
15. Double-blind, placebo-controlled, randomized phase 2 study of the proapoptotic agent AT-101 plus docetaxel, in second-line non-small cell lung cancer.
Ready N; Karaseva NA; Orlov SV; Luft AV; Popovych O; Holmlund JT; Wood BA; Leopold L
J Thorac Oncol; 2011 Apr; 6(4):781-5. PubMed ID: 21289522
[TBL] [Abstract][Full Text] [Related]
16. Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR).
Lee JS; Hirsh V; Park K; Qin S; Blajman CR; Perng RP; Chen YM; Emerson L; Langmuir P; Manegold C
J Clin Oncol; 2012 Apr; 30(10):1114-21. PubMed ID: 22370318
[TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy.
Yoh K; Hosomi Y; Kasahara K; Yamada K; Takahashi T; Yamamoto N; Nishio M; Ohe Y; Koue T; Nakamura T; Enatsu S; Lee P; Ferry D; Tamura T; Nakagawa K
Lung Cancer; 2016 Sep; 99():186-93. PubMed ID: 27565938
[TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer.
Kiura K; Nakagawa K; Shinkai T; Eguchi K; Ohe Y; Yamamoto N; Tsuboi M; Yokota S; Seto T; Jiang H; Nishio K; Saijo N; Fukuoka M
J Thorac Oncol; 2008 Apr; 3(4):386-93. PubMed ID: 18379357
[TBL] [Abstract][Full Text] [Related]
19. Vandetanib plus chemotherapy for induction followed by vandetanib or placebo as maintenance for patients with advanced non-small-cell lung cancer: a randomized phase 2 PrECOG study (PrE0501).
Aisner J; Manola JB; Dakhil SR; Stella PJ; Sovak MA; Schiller JH
J Thorac Oncol; 2013 Aug; 8(8):1075-83. PubMed ID: 23689430
[TBL] [Abstract][Full Text] [Related]
20. Phase II randomized study of vandetanib plus gemcitabine or gemcitabine plus placebo as first-line treatment of advanced non-small-cell lung cancer in elderly patients.
Gridelli C; Novello S; Zilembo N; Luciani A; Favaretto AG; De Marinis F; Genestreti G; Crinò L; Grossi F; Caffo O; Ferraù F; Cruciani G; Brandes AA; Galetta D; Barni S; Fasola G; Cerea G; Ferrari S; Iannacone C; Ciardiello F
J Thorac Oncol; 2014 May; 9(5):733-7. PubMed ID: 24722160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
